DMDaniela Olivera Mesa

Daniela Olivera Mesa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniela Olivera Mesa has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidemiological characteristics and vaccination impact scenario modelling of concurrent Clade I mpox outbreaks in the Democratic Republic of the Congo and Burundi

    by Ruth McCabe, Edward Knock, Alba Halliday, Victoria M Cox, Daniela Olivera Mesa, Kieran Chopra, Brian Ajong, Jean-Claude Bizimana, Thierry Kalonji, Olivier Kamatari, et al.

    In 2024, mpox cases surged in the Democratic Republic of the Congo (DRC) with cross-border spread to Burundi. We developed a transmission-dynamic model calibrated against surveillance data to understand drivers in enzootic (Clade Ia) and non-enzootic (Clade Ib) areas, and the potential impact of vaccination. In non-enzootic areas we estimated that 58-84% of transmission occurred within sexual networks. MVA-BN vaccination of sex workers could have averted 91% (95% CrI 81%–98%) of infections in Sud Kivu (DRC) but only 35% (95% CrI 26%–47%) in Bujumbura (Burundi), due to later outbreak detection. In historically enzootic Equateur (DRC), ongoing zoonotic spillover best explained sustained incidence. There, pledged Lc18m8 vaccines could have averted 42% (95% CrI 40%–46%) of infections; prioritising children improved impact. Across all settings, doubling vaccine coverage by using a single dose of MVA-BN outperformed two-dose strategies. Timely detection and tailored vaccination strategies are critical to reducing mpox burden.


  • Open Access

    Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic

    by Charles Whittaker, Gregory Barnsley, Daniela Olivera Mesa, Victoria Cox, Daniel J. Laydon, Chee Wah Tan, Feng Zhu, Rob Johnson, Patrick Doohan, Lilith K. Whittles, et al.

    COVID-19 has underscored the need for more timely access to vaccines during future pandemics. This has motivated development of broad-spectrum vaccines providing protection against entire viral families, which could be stockpiled and deployed rapidly following detection. Using mathematical modelling, we assess the utility of a broadly protective sarbecovirus vaccine during a hypothetical SARS-X outbreak, for a range of implementation strategies including ring-vaccination, spatial-targeting and mass vaccination of high-risk groups. Broadly protective sarbecovirus vaccine ring- or spatial strategies alone are insufficient to contain epidemics driven by a SARS-CoV-2-like virus, but when paired with rapid isolation and quarantine, can achieve containment of a SARS-CoV-1-like virus. Where suppression fails, broadly protective sarbecovirus vaccine utilisation still reduces the effective reproduction number and slows epidemic growth - buying valuable time for health-system response and virus-specific vaccine development. Vaccination of high-risk populations with the broadly protective sarbecovirus vaccine ahead of virus-specific vaccine availability could reduce mortality and enable shorter and less stringent non-pharmaceutical interventions to be imposed; results are sensitive to vaccine properties (e.g., efficacy), health system capabilities (e.g. rollout speed) and timeline to virus-specific vaccine availability. Our modelling suggests that broadly protective sarbecovirus vaccine delivery to those aged 60+ years could have averted 21-78 % of COVID-19 deaths during the pandemic’s first year, depending on the size of the stockpile. Realising this potential impact will require investment in manufacturing, delivery capacity and equitable access ahead of future pandemics.


  • Open Access

    Author Correction: Using mortuary and burial data to place COVID-19 in Lusaka, Zambia within a global context

    by Richard J. Sheppard, Oliver J. Watson, Rachel Pieciak, James Lungu, Geoffrey Kwenda, Crispin Moyo, Stephen Longa Chanda, Gregory Barnsley, Nicholas F. Brazeau, Ines C. G. Gerard-Ursin, et al.

  • Open Access

    Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study

    by Alexandra B Hogan, Sean L Wu, Jaspreet Toor, Daniela Olivera Mesa, Patrick Doohan, Oliver J Watson, Peter Winskill, Giovanni Charles, Gregory Barnsley, Eleanor M Riley, et al.

    Background: Vaccines have reduced severe disease and death from Coronavirus Disease 2019 (COVID-19). However, with evidence of waning efficacy coupled with continued evolution of the virus, health programmes need to evaluate the requirement for regular booster doses, considering their impact and cost-effectiveness in the face of ongoing transmission and substantial infection-induced immunity. Methods and findings: We developed a combined immunological-transmission model parameterised with data on transmissibility, severity, and vaccine effectiveness. We simulated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and vaccine rollout in characteristic global settings with different population age-structures, contact patterns, health system capacities, prior transmission, and vaccine uptake. We quantified the impact of future vaccine booster dose strategies with both ancestral and variant-adapted vaccine products, while considering the potential future emergence of new variants with modified transmission, immune escape, and severity properties. We found that regular boosting of the oldest age group (75+) is an efficient strategy, although large numbers of hospitalisations and deaths could be averted by extending vaccination to younger age groups. In countries with low vaccine coverage and high infection-derived immunity, boosting older at-risk groups was more effective than continuing primary vaccination into younger ages in our model. Our study is limited by uncertainty in key parameters, including the long-term durability of vaccine and infection-induced immunity as well as uncertainty in the future evolution of the virus. Conclusions: Our modelling suggests that regular boosting of the high-risk population remains an important tool to reduce morbidity and mortality from current and future SARS-CoV-2 variants. Our results suggest that focusing vaccination in the highest-risk cohorts will be the most efficient (and hence cost-effective) strategy to reduce morbidity and mortality.


  • Open Access

    Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach

    by Alexandra B. Hogan, Patrick Doohan, Sean L. Wu, Daniela Olivera Mesa, Jaspreet Toor, Oliver J. Watson, Peter Winskill, Giovanni Charles, Gregory Barnsley, Eleanor M. Riley, et al.

    With the ongoing evolution of the SARS-CoV-2 virus updated vaccines may be needed. We fitted a model linking immunity levels and protection to vaccine effectiveness data from England for three vaccines (Oxford/AstraZeneca AZD1222, Pfizer-BioNTech BNT162b2, Moderna mRNA-1273) and two variants (Delta, Omicron). Our model reproduces the observed sustained protection against hospitalisation and death from the Omicron variant over the first six months following dose 3 with the ancestral vaccines but projects a gradual waning to moderate protection after 1 year. Switching the fourth dose to a variant-matched vaccine against Omicron BA.1/2 is projected to prevent nearly twice as many hospitalisations and deaths over a 1-year period compared to administering the ancestral vaccine. This result is sensitive to the degree to which immunogenicity data can be used to predict vaccine effectiveness and uncertainty regarding the impact that infection-induced immunity (not captured here) may play in modifying future vaccine effectiveness.


  • Open Access

    Using mortuary and burial data to place COVID-19 in Lusaka, Zambia within a global context

    by Richard J. Sheppard, Oliver J. Watson, Rachel Pieciak, James Lungu, Geoffrey Kwenda, Crispin Moyo, Stephen Longa Chanda, Gregory Barnsley, Nicholas F. Brazeau, Ines C. G. Gerard-Ursin, et al.

    Reported COVID-19 cases and associated mortality remain low in many sub-Saharan countries relative to global averages, but true impact is difficult to estimate given limitations around surveillance and mortality registration. In Lusaka, Zambia, burial registration and SARS-CoV-2 prevalence data during 2020 allow estimation of excess mortality and transmission. Relative to pre-pandemic patterns, we estimate age-dependent mortality increases, totalling 3212 excess deaths (95% CrI: 2104–4591), representing an 18.5% (95% CrI: 13.0–25.2%) increase relative to pre-pandemic levels. Using a dynamical model-based inferential framework, we find that these mortality patterns and SARS-CoV-2 prevalence data are in agreement with established COVID-19 severity estimates. Our results support hypotheses that COVID-19 impact in Lusaka during 2020 was consistent with COVID-19 epidemics elsewhere, without requiring exceptional explanations for low reported figures. For more equitable decision-making during future pandemics, barriers to ascertaining attributable mortality in low-income settings must be addressed and factored into discourse around reported impact differences.


  • Open Access

    The societal cost of vaccine refusal: A modelling study using measles vaccination as a case study

    by Daniela Olivera Mesa, Peter Winskill, Azra C Ghani, Katharina Hauck


  • Open Access

    Modelling the impact of vaccine hesitancy in prolonging the need for Non-Pharmaceutical Interventions to control the COVID-19 pandemic

    by Daniela Olivera Mesa, Alexandra B. Hogan, Oliver J. Watson, Giovanni D. Charles, Katharina Hauck, Azra C. Ghani, Peter Winskill

    Background: Vaccine hesitancy – a delay in acceptance or refusal of vaccines despite availability – has the potential to threaten the successful roll-out of SARS-CoV-2 vaccines globally. In this study, we aim to understand the likely impact of vaccine hesitancy on the control of the COVID-19 pandemic. Methods: We modelled the potential impact of vaccine hesitancy on the control of the pandemic and the relaxation of non-pharmaceutical interventions (NPIs) by combining an epidemiological model of SARS-CoV-2 transmission with data on vaccine hesitancy from population surveys. Results: Our simulations suggest that the mortality over a 2-year period could be up to 7.6 times higher in countries with high vaccine hesitancy compared to an ideal vaccination uptake if NPIs are relaxed. Alternatively, high vaccine hesitancy could prolong the need for NPIs to remain in place. Conclusions: While vaccination is an individual choice, vaccine-hesitant individuals have a substantial impact on the pandemic trajectory, which may challenge current efforts to control COVID-19. In order to prevent such outcomes, addressing vaccine hesitancy with behavioural interventions is an important priority in the control of the COVID-19 pandemic.


  • Open Access

    Quantifying the impact of vaccine hesitancy in prolonging the need for Non-Pharmaceutical Interventions to control the COVID-19 pandemic

    by Daniela Olivera Mesa, Alexandra Hogan, Oliver Watson, Giovanni Charles, Katharina Hauck, Azra C Ghani, Peter Winskill

    Vaccine hesitancy – a delay in acceptance or refusal of vaccines despite availability – has the potential to threaten the successful roll-out of SARS-CoV-2 vaccines globally. Here, we evaluate the potential impact of vaccine hesitancy on the control of the pandemic and the relaxation of non-pharmaceutical interventions (NPIs) by combining an epidemiological model of SARS-CoV-2 transmission with data on vaccine hesitancy from population surveys. Our findings suggest that the mortality over a 2-year period could be up to 8 times higher in countries with high vaccine hesitancy compared to an ideal vaccination uptake if NPIs are relaxed. Alternatively, high vaccine hesitancy could prolong the need for NPIs to remain in place. Addressing vaccine hesitancy with behavioural interventions is therefore an important priority in the control of the COVID-19 pandemic.


  • Open Access

    Predicting the public health impact of a malaria transmission-blocking vaccine

    by Joseph D. Challenger, Daniela Olivera Mesa, Dari F. Da, R. Serge Yerbanga, Thierry Lefèvre, Anna Cohuet, Thomas S. Churcher

    Transmission-blocking vaccines that interrupt malaria transmission from humans to mosquitoes are being tested in early clinical trials. The activity of such a vaccine is commonly evaluated using membrane-feeding assays. Understanding the field efficacy of such a vaccine requires knowledge of how heavily infected wild, naturally blood-fed mosquitoes are, as this indicates how difficult it will be to block transmission. Here we use data on naturally infected mosquitoes collected in Burkina Faso to translate the laboratory-estimated activity into an estimated activity in the field. A transmission dynamics model is then utilised to predict a transmission-blocking vaccine’s public health impact alongside existing interventions. The model suggests that school-aged children are an attractive population to target for vaccination. Benefits of vaccination are distributed across the population, averting the greatest number of cases in younger children. Utilising a transmission-blocking vaccine alongside existing interventions could have a substantial impact against malaria.